Nat Mulkey, MD, Carl G. Streed Jr, MD, MPH, and Barbara M. Chubak, MD
Some clinicians cite absence of long-term data to justify not fully deferring surgery for children with DSD, and legal restrictions of early procedures are also at play.
AMA J Ethics. 2021; 23(7):E550-556. doi:
10.1001/amajethics.2021.550.
Carly P. Smith, PhD and Daniel R. George, PhD, MSc
Invisibility of racial inequity and gender inclusion in clinical research means key features of disease etiology and symptom presentation are unaccounted for.
AMA J Ethics. 2021; 23(7):E563-568. doi:
10.1001/amajethics.2021.563.
Eleftherios Mylonakis, MD and Panayiotis D. Ziakas, MD, MSc, PhD
Allocating resources for interventions requires consensus among stakeholders with a plurality of perspectives about how to weigh antimicrobial stewardship interventions’ risks and benefits.
AMA J Ethics. 2021; 23(8):E631-638. doi:
10.1001/amajethics.2021.631.
Dr Nat Mulkey and Dr Carl G. Streed Jr join Ethics Talk to discuss their article coauthored with Dr Barbara M. Chubak, "A Call to Update Standard of Care for Children With Differences in Sex Development."
A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021; 23(9):E712-720. doi:
10.1001/amajethics.2021.712.